Caliway Biopharmaceuticals Co., Ltd.
Quick facts
Phase 3 pipeline
- CBL-514 · Oncology
CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: